AB-106
Phase 2Terminated 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumor
Conditions
Solid Tumor
Trial Timeline
Jun 1, 2021 → Dec 6, 2024
NCT ID
NCT04617054About AB-106
AB-106 is a phase 2 stage product being developed by Nuvation Bio for Solid Tumor. The current trial status is terminated. This product is registered under clinical trial identifier NCT04617054. Target conditions include Solid Tumor.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04617054 | Phase 2 | Terminated |
| NCT04395677 | Phase 2 | Active |
Competing Products
20 competing products in Solid Tumor